Wave Life Sciences Research Day - WAVE LIFE SCIENCES INC

Financial Performance:

• No specific GAAP financial metrics (revenue, net income, cash flow, debt) were disclosed as WAVE is a pre-revenue biotechnology company focused on clinical development.
• Management emphasized a "cost-effective" manufacturing process and the strategic use of their proprietary chemistry to advance candidates without "additional cost to standard oligo development."
• The company reported significant preclinical success with WVE-006 (AATD), demonstrating durable RNA editing and safety, serving as a validated platform foundation without current commercial revenue.
• No mention of deferred revenue or specific debt levels, reflecting the company's stage of development and reliance on capital for R&D.

Guidance and Future Outlook:

• WVE-008 (PNPLA3): Aiming to file a Clinical Trial Application (CTA) in Q4 of the current year to initiate Phase 1 trials in homozygous I148M patients.
• WVE-007 (Inhibiti): Plans to initiate a maintenance trial and share data from the 600 mg cohort of the Phase 1 ENLIGHT trial.
• WVE-006 (Restoration II): Scheduled to share data from the 600 mg cohort of the Restoration II clinical trial.
• Platform Expansion: Continued focus on extending delivery to extra-hepatic tissues (kidney, adipose) via PN conjugates and advancing bifunctional modalities for complex indications.
• Long-term Goal: To establish a first-in-class, disease-modifying treatment for PNPLA3-driven liver disease and unlock new therapeutic targets via multi-modal RNA editing and silencing.

Business Segments and Product Lines:

• WVE-008 (PNPLA3 Liver Disease): A galactose-conjugated RNA editing candidate targeting the I148M mutation. Preclinical data shows >60% editing in hepatic stellate cells and hepatocytes, reducing liver fat and fibrosis markers. Mechanism focuses on restoring wild-type function rather than silencing.
• WVE-007 (Inhibiti): A SPINA design siRNA targeting the inhibitory subunit of AMPK. Phase 1 data shows >7 months of potent, dose-dependent suppression of serum inhibin with >10x improvement in AGO2 loading compared to references. Demonstrated reduction in visceral fat and preservation of lean mass.
• WVE-006 (AATD): Clinically validated RNA editing program for Alpha-1 Antitrypsin Deficiency, showing target engagement, durable editing, and safety.
• SPINA Platform: Stereopure interfering nucleic acid designs delivering >10x improvement in AGO2 loading, potency, and durability compared to industry benchmarks (e.g., TTR, PCSK9, Inhibiti).
• Bifunctional Modalities: New constructs capable of silencing, editing, and/or upregulating two distinct targets simultaneously (e.g., silencing PCSK9 while upregulating LDLR; silencing LPA while silencing PCSK9).
• PN Conjugates: Proprietary backbone chemistry enabling tunable tissue distribution beyond the liver, successfully demonstrated in kidney (SOD1 knockdown) and adipose tissue.

Market and Competitive Landscape:

• Target Market: ~9 million homozygous individuals in the US/Europe carry the PNPLA3 I148M mutation, associated with high risk of MASLD, cirrhosis, and HCC.
• Competitive Differentiation: WAVE argues against PNPLA3 silencing (siRNA), citing preclinical data where knockdown worsened steatosis/inflammation/fibrosis. Their RNA editing approach restores function, addressing the gain-of-function pathology.
• Therapeutic Gap: No approved therapies exist that directly target the genetic driver of PNPLA3 disease; current GLP-1 therapies show weaker MASH resolution in mutation carriers.
• Obesity/Liver Segment: Inhibiti targets an orthogonal mechanism to GLP-1s, preserving muscle mass and preventing weight regain post-cessation in preclinical models.

Risks and Challenges:

• Clinical Validation: The novel RNA editing modality for PNPLA3 requires de-risking in humans to prove efficacy in reversing fibrosis and inflammation, not just reducing steatosis.
• Disease Complexity: Liver disease progression is slow; demonstrating clinical benefit (fibrosis reversal) requires long-term follow-up or robust surrogate endpoints.
• Patient Enrichment: Reliance on genotyping to identify the specific homozygous population; while commercially available, large-scale screening infrastructure for trial recruitment may present logistical hurdles.
• Off-target Effects: Management emphasized high specificity in editing with no off-targets observed in preclinical models, but long-term safety remains a development risk.

Management Commentary and Tone:

• Confidence: Management expressed high conviction in the platform's differentiation, citing the Nobel Prize in Chemistry recognition for stereochemistry and the clinical validation of RNA editing via WVE-006.
• Strategic Focus: Emphasis on "rational drug design," "stereopure" chemistry, and the ability to rapidly translate candidates (e.g., WVE-007 in 18 months).
• Collaboration: Acknowledged partnerships (e.g., GSK for GSK program) as validation of the SPINA platform's scalability and potential for future commercialization or licensing.
• Tone: Optimistic yet pragmatic, acknowledging the need for specific patient populations and the complexity of liver disease endpoints.

Analyst Questions and Answers:

• Prevention vs. Treatment: Confirmed the goal is both prevention of progression and therapeutic reversal of existing steatosis/fibrosis, as the mutation drives disease across all stages.
• Dosing Efficacy: Inhibiti efficacy is correlated with baseline adiposity; minimal effect in lean mice, significant weight/fat loss in obese models, translating to human Phase 2A trials in higher BMI cohorts.
• Editing Mechanism: The RNA editing corrects the mutation to a Valine (I148V) substitution rather than wild-type Isoleucine, supported by conservation data across species, which is functionally equivalent and restores lipid homeostasis.
• Trial Design: Phase 1 for WVE-008 will utilize genotype-enriched populations to accelerate enrollment and signal detection, focusing on editing efficiency, biomarker changes (steatosis, fibrosis markers), and safety.
• Partnership Strategy: Open to partnering on specific targets/programs to optimize capital efficiency, with the platform already validated by internal success and GSK partnership.
• Biomarkers: Will track MRI-PDFF for liver fat, liver enzymes for injury, and emerging fibrosis markers (PRO-C3, NIS2+) to differentiate from silencing approaches.
• CIDEB vs. PNPLA3: Different mechanisms; PNPLA3 correction addresses the direct genetic driver in a large homogeneous population, whereas other fat-reducing mechanisms may complement but not replace this approach.

Other Key Points:

• Stereochemistry: Highlighted as a core differentiator; WAVE synthesizes single stereoisomers to ensure consistent pharmacology and safety profiles, avoiding the "stereorandom mixture" issues of traditional oligos.
• Extra-hepatic Delivery: Successfully demonstrated silencing in adipose tissue (90% knockdown) and kidney (75% SOD1 knockdown) using tunable PN conjugates, expanding the addressable market beyond the liver.
• Upregulation: Introduced a novel modality using RNA editing to disrupt regulatory motifs in mRNA, stabilizing transcripts to increase protein production without introducing exogenous genes.
• Bifunctional Synergy: Preclinical data shows >5-fold upregulation of a target when paired with silencing of another in a single construct, demonstrating synergistic potential for complex indications.
• Genotyping Availability: Confirmed that PNPLA3 genotyping is commercially available (e.g., 23andMe) and in major genetic databases, facilitating patient identification for trials.